[go: up one dir, main page]

DK4058148T3 - Doseringsregime for anti-bcma-midler - Google Patents

Doseringsregime for anti-bcma-midler Download PDF

Info

Publication number
DK4058148T3
DK4058148T3 DK20729951.2T DK20729951T DK4058148T3 DK 4058148 T3 DK4058148 T3 DK 4058148T3 DK 20729951 T DK20729951 T DK 20729951T DK 4058148 T3 DK4058148 T3 DK 4058148T3
Authority
DK
Denmark
Prior art keywords
bcma
agents
dosage regime
regime
dosage
Prior art date
Application number
DK20729951.2T
Other languages
English (en)
Other versions
DK4058148T5 (da
Inventor
Julia Stieglmaier
Birgit Huber
Vijay Upreti
Alexander Minella
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4058148(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh, Amgen Inc filed Critical Amgen Res Munich Gmbh
Publication of DK4058148T3 publication Critical patent/DK4058148T3/da
Application granted granted Critical
Publication of DK4058148T5 publication Critical patent/DK4058148T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK20729951.2T 2019-11-11 2020-05-08 Doseringsregime for anti-bcma-midler DK4058148T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007B1 (en) 2019-11-11 2019-11-11 Dosing regimen for anti-bcma agents
PCT/EP2020/062876 WO2021094000A1 (en) 2019-11-11 2020-05-08 Dosing regimen for anti-bcma agents

Publications (2)

Publication Number Publication Date
DK4058148T3 true DK4058148T3 (da) 2024-05-06
DK4058148T5 DK4058148T5 (da) 2024-07-22

Family

ID=68581157

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19208417.6T DK3819007T3 (da) 2019-11-11 2019-11-11 Doseringsplan for anti-bcma-midler
DK20729951.2T DK4058148T5 (da) 2019-11-11 2020-05-08 Doseringsregime for anti-bcma-midler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19208417.6T DK3819007T3 (da) 2019-11-11 2019-11-11 Doseringsplan for anti-bcma-midler

Country Status (20)

Country Link
US (1) US20210139584A1 (da)
EP (3) EP3819007B1 (da)
JP (2) JP2022554362A (da)
AU (1) AU2020381671A1 (da)
CA (1) CA3155069A1 (da)
DK (2) DK3819007T3 (da)
ES (2) ES2987783T3 (da)
FI (2) FI3819007T3 (da)
HR (2) HRP20241281T1 (da)
HU (2) HUE068401T2 (da)
LT (2) LT3819007T (da)
MA (1) MA47888B1 (da)
MX (1) MX2022005628A (da)
PL (2) PL3819007T3 (da)
PT (2) PT3819007T (da)
RS (2) RS65943B1 (da)
SI (2) SI3819007T1 (da)
SM (2) SMT202400373T1 (da)
TW (1) TW202118784A (da)
WO (1) WO2021094000A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
TW202233682A (zh) * 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
JP2024541668A (ja) * 2021-12-03 2024-11-08 山▲東▼先声生物制▲薬▼有限公司 抗ｂｃｍａナノ抗体及びその応用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
PL199747B1 (pl) 1998-04-21 2008-10-31 Micromet Ag Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1100830B1 (en) 1998-07-28 2003-10-01 Micromet AG Heterominibodies
ATE493441T1 (de) 2003-10-16 2011-01-15 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
NZ580755A (en) 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
PL2748201T3 (pl) 2011-08-23 2018-04-30 Roche Glycart Ag Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104736559B (zh) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 白蛋白变体
RU2670063C2 (ru) 2012-11-08 2018-10-17 Альбумедикс А/С Варианты альбумина
EP3424952A1 (en) 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PL3283106T3 (pl) 2015-04-13 2022-05-02 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
JP2018525005A (ja) 2015-08-17 2018-09-06 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｂｃｍａ抗体、ｂｃｍａ及びｃｄ３に結合する二重特異性抗原結合分子、並びにそれらの使用
IL260958B2 (en) * 2016-02-03 2024-11-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202005605SA (en) * 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
HUE061792T2 (hu) 2018-05-23 2023-08-28 Celgene Corp Antiproliferatív vegyületek és BCMA és CD3 elleni bispecifikus antitest kombinált alkalmazásra
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
UY38393A (es) * 2018-09-28 2020-03-31 Amgen Inc Anticuerpos contra bcma soluble
EP3911371A4 (en) * 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
JP2022538237A (ja) 2019-06-24 2022-09-01 ノバルティス アーゲー Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
DK3766701T3 (da) 2019-07-18 2023-07-03 Barberan Latorre Jesus Francisco Hoved, maskine og fremgangsmåde til digital udskrivning på underlag
US20230057602A1 (en) 2019-11-05 2023-02-23 Bristol-Myers Squibb Company Methods of treatment with antibodies against bcma and cd3
AU2021345124A1 (en) * 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
TW202233682A (zh) * 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法

Also Published As

Publication number Publication date
WO2021094000A1 (en) 2021-05-20
PL3819007T3 (pl) 2024-11-18
DK3819007T3 (da) 2024-09-30
HUE068401T2 (hu) 2024-12-28
HUE066166T2 (hu) 2024-07-28
EP4058148A1 (en) 2022-09-21
JP2022554362A (ja) 2022-12-28
LT4058148T (lt) 2024-05-27
FI3819007T3 (fi) 2024-09-25
PT4058148T (pt) 2024-05-03
ES2987783T3 (es) 2024-11-18
LT3819007T (lt) 2024-10-10
EP3819007A1 (en) 2021-05-12
PL4058148T3 (pl) 2024-09-16
SMT202400373T1 (it) 2024-11-15
RS65943B1 (sr) 2024-10-31
FI4058148T3 (fi) 2024-05-06
HRP20240553T1 (hr) 2024-07-05
MA47888B1 (fr) 2024-10-31
EP4424709A3 (en) 2024-12-11
SI4058148T1 (sl) 2024-06-28
US20210139584A1 (en) 2021-05-13
MX2022005628A (es) 2022-06-14
SMT202400165T1 (it) 2024-05-14
EP4424709A2 (en) 2024-09-04
CA3155069A1 (en) 2021-05-20
AU2020381671A1 (en) 2022-03-31
ES2987070T3 (es) 2024-11-13
SI3819007T1 (sl) 2024-10-30
PT3819007T (pt) 2024-09-20
EP4058148B1 (en) 2024-03-13
EP3819007B1 (en) 2024-07-10
JP2025170264A (ja) 2025-11-18
TW202118784A (zh) 2021-05-16
DK4058148T5 (da) 2024-07-22
HRP20241281T1 (hr) 2024-12-06
RS65581B1 (sr) 2024-06-28

Similar Documents

Publication Publication Date Title
IL292753A (en) Compounds
EP4007752C0 (en) KIF18A INHIBITORS
EP4007753C0 (en) KIF18A INHIBITORS
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
EP3911378C0 (de) Verbessertes modulares verabreichungsgerät
IL282330A (en) Therapeutic compounds
JP1719667S (ja) ディスペンサー
LT3768284T (lt) Enterecoccus flagelino kompozicijos, skirtos panaudoti terapijai
EP4054636A4 (en) DOSAGE REGIME FOR ANTI-DLL3 AGENTS
DK3946179T4 (da) Stomiposer
IL283900A (en) Pharmaceutical combinations
DK4058148T3 (da) Doseringsregime for anti-bcma-midler
EP3810063A4 (en) Individual dose pack
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
DK3908321T3 (da) Farmaceutisk sammensætning
EP3831399A4 (en) AGENT AGAINST NOROVIRUS
IL269169A (en) Novel dosage form
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais
PL4009942T3 (pl) Związek służący do leczenia skojarzonego
EP3785686C0 (en) DELIVERY TABLE
PT3949952T (pt) Composição farmacêutica
EP4061375A4 (en) REMEDIES AGAINST MALARIA
IL285046A (en) Anti-apicomplexan compositions
EP4051061C0 (en) ADJUSTABLE DOSING MEANS
PL3965739T3 (pl) Postacie dawkowane będące tabletkami oleilofosfocholiny